Please login (Members) to view content or
(Nonmembers) this article.
No votes yet

Brachytherapy: Increased Use in Patients With Intermediate- and High-Risk Prostate Cancers

Sanna Ali
Peg Esper
CJON 2021, 25(3), 321-328 DOI: 10.1188/21.CJON.321-328

Background: Brachytherapy is a well-established and effective primary treatment modality for low- and favorable intermediate–risk prostate cancers. Although the benefits of brachytherapy in unfavorable intermediate– and high-risk prostate cancers have not been as clear, research suggests that brachytherapy boost may improve biochemical progression-free survival in these patients.

Objectives: This article aims to discuss evidence for the revival of brachytherapy use in unfavorable intermediate– and high-risk prostate cancers and specific nursing implications in the management of these patients.

Methods: The literature on brachytherapy and its use to treat localized prostate cancers was reviewed.

Findings: Nurses should be knowledgeable about the indications for brachytherapy, patient eligibility, anticipated side effects, and symptom management.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or